Now PlayingEP. 1 Introduction and CAR-T Therapy in Earlier Lines of Treatment for R/R Multiple Myeloma
EP. 4 Referral Process for CAR T-Cell Therapy: Initial Contact Through Patient Evaluation and Selection
EP. 6 Co-Management and Co-Monitoring of Patients Receiving CAR T-Cell Treatment: Transitions Between the Academic and Community Centers
EP. 7 Management of Adverse Events of Special Interest in Patients Receiving CAR -T-Cell Therapy for R/R Multiple Myeloma: Diarrhea, Guillain-Barrée Syndrome, Parkinson’s Disease, and Secondary Malignancies
November 18th, 2026How Should CAR T and Bispecifics Be Sequenced in Multiple Myeloma?Ajai Chari, MD, discussed sequencing CAR T and bispecifics, fixed-duration therapy, emerging targets, and academic partnership in multiple myeloma.Read more
November 18th, 2026Why CAR T May Belong Before Bispecifics in Multiple MyelomaAt the 2026 Chemotherapy Foundation Symposium, Ajai Chari, MD, explained how disease pace and BCMA sequencing guide choosing CAR T or bispecifics.Read more
November 16th, 2026Remote Monitoring Strategies for CRS During Outpatient Bispecific TherapyRalph V. Boccia, MD, FACP, details the home monitoring tools, prophylaxis, and grade-based approach his practice uses to manage CRS.Read more
November 15th, 2026Partnering With Local Hospitals to Manage CRS and ICANS From Bispecific AntibodiesRalph V. Boccia, MD, FACP, discussed educating hospital teams and using tocilizumab to manage bispecific toxicities when patients need admission.Read more
November 14th, 2026Managing Emergencies During Outpatient Bispecific Step-Up DosingRalph V. Boccia, MD, FACP, noted how designated hospitals and a 24/7 on-call team support emergencies during bispecific step-up dosing.Read more
November 13th, 2026Why Caregivers Are Critical During Bispecific Step-Up DosingRalph V. Boccia, MD, FACP, explained the caregiver’s role in monitoring and reporting during bispecific antibody step-up dosing.Read more
November 13th, 2026REMS Certification and Team-Wide Training for Bispecific Administration in Multiple MyelomaRalph V. Boccia, MD, FACP, explained who needs REMS certification and which care team members need training to deliver bispecific antibodies.Read more
November 13th, 2026Optimal Cytoreduction and Early Trial Referral in High-Risk Newly Diagnosed MyelomaSaad Z. Usmani, MD, MBA, FACP, FASCO, discussed quadruplet induction, extended maintenance, and when a community clinician should call a myeloma center.Read more